Ixoberogene soroparvovec
Gene therapyexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 14, 2018 (NCT03748784)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095443 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06856577 | Phase 3 | Feb 28, 2025 | Adverum Biotechnologies, Inc. |
| NCT05536973 | Phase 2 | Aug 23, 2022 | Adverum Biotechnologies, Inc., Parexel |
| NCT04418427 | Phase 2 | May 28, 2020 | Adverum Biotechnologies, Inc. |
| NCT03748784 | Phase 1 | Nov 14, 2018 | Adverum Biotechnologies, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. | For profit | 4 | 4 | 3 | 2018 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1